Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

More information: Ling Cai et al, High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients, Cancer Discovery (2025). DOI: 10.1158/2159-8290.CD ...